Literature DB >> 16841194

Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model.

Xianhua Cao1, Seth T Gibbs, Lanyan Fang, Heather A Miller, Christopher P Landowski, Ho-Chul Shin, Hans Lennernas, Yanqiang Zhong, Gordon L Amidon, Lawrence X Yu, Duxin Sun.   

Abstract

PURPOSE: To study the correlation of intestinal absorption for drugs with various absorption routes between human and rat, and to explore the underlying molecular mechanisms for the similarity in drug intestinal absorption and the differences in oral bioavailability between human and rat.
MATERIALS AND METHODS: The intestinal permeabilities of 14 drugs and three drug-like compounds with different absorption mechanisms in rat and human jejunum were determined by in situ intestinal perfusion. A total of 48 drugs were selected for oral bioavailability comparison. Expression profiles of transporters and metabolizing enzymes in both rat and human intestines (duodenum and colon) were measured using GeneChip analysis.
RESULTS: No correlation (r(2) = 0.29) was found in oral drug bioavailability between rat and human, while a correlation (r(2) = 0.8) was observed for drug intestinal permeability with both carrier-mediated absorption and passive diffusion mechanisms between human and rat small intestine. Moderate correlation (with r(2) > 0.56) was also found for the expression levels of transporters in the duodenum of human and rat, which provides the molecular mechanisms for the similarity and correlation of drug absorption between two species. In contrast, no correlation was found for the expressions of metabolizing enzymes between rat and human intestine, which indicates the difference in drug metabolism and oral bioavailability in two species. Detailed analysis indicates that many transporters (such as PepT1, SGLT-1, GLUT5, MRP2, NT2, and high affinity glutamate transporter) share similar expression levels in both human and rat with regional dependent expression patterns, which have high expression in the small intestine and low expression in the colon. However, discrepancy was also observed for several other transporters (such as MDR1, MRP3, GLUT1, and GLUT3) in both the duodenum and colon of human and rat. In addition, the expressions of metabolizing enzymes (CYP3A4/CYP3A9 and UDPG) showed 12 to 193-fold difference between human and rat intestine with distinct regional dependent expression patterns.
CONCLUSIONS: The data indicate that rat and human show similar drug intestinal absorption profiles and similar transporter expression patterns in the small intestine, while the two species exhibit distinct expression levels and patterns for metabolizing enzymes in the intestine. Therefore, a rat model can be used to predict oral drug absorption in the small intestine of human, but not to predict drug metabolism or oral bioavailability in human.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16841194     DOI: 10.1007/s11095-006-9041-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  80 in total

1.  Bioavailability of codeine preparations in the rat.

Authors:  M Strolin Benedetti; D A Larue
Journal:  Arzneimittelforschung       Date:  1973-06

2.  The validation of the intestinal permeability approach to predict oral fraction of dose absorbed in humans and rats.

Authors:  W L Chiou
Journal:  Biopharm Drug Dispos       Date:  1995-01       Impact factor: 1.627

3.  Immuno-localization of H+/peptide cotransporter in rat digestive tract.

Authors:  H Ogihara; H Saito; B C Shin; T Terado; S Takenoshita; Y Nagamachi; K Inui; K Takata
Journal:  Biochem Biophys Res Commun       Date:  1996-03-27       Impact factor: 3.575

4.  Pharmacokinetics of methyldopa in man.

Authors:  K C Kwan; E L Foltz; G O Breault; J E Baer; J A Totaro
Journal:  J Pharmacol Exp Ther       Date:  1976-08       Impact factor: 4.030

5.  Chronic nifedipine dosing enhances cephalexin bioavailability and intestinal absorption in conscious rats.

Authors:  F Berlioz; B Lepére-Prevot; S Julien; A Tsocas; C Carbon; C Rozé; R Farinotti
Journal:  Drug Metab Dispos       Date:  2000-11       Impact factor: 3.922

6.  Predicting fraction dose absorbed in humans using a macroscopic mass balance approach.

Authors:  P J Sinko; G D Leesman; G L Amidon
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

7.  Isosorbide 5-mononitrate kinetics.

Authors:  R M Major; T Taylor; L F Chasseaud; A Darragh; R F Lambe
Journal:  Clin Pharmacol Ther       Date:  1984-05       Impact factor: 6.875

8.  Comparison of oral absorption and bioavailablity of drugs between monkey and human.

Authors:  Win L Chiou; Paul W Buehler
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

9.  CYP3A gene expression in human gut epithelium.

Authors:  J C Kolars; K S Lown; P Schmiedlin-Ren; M Ghosh; C Fang; S A Wrighton; R M Merion; P B Watkins
Journal:  Pharmacogenetics       Date:  1994-10

10.  Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.

Authors:  J C Kolars; P Schmiedlin-Ren; J D Schuetz; C Fang; P B Watkins
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

View more
  60 in total

Review 1.  Applications of human pharmacokinetic prediction in first-in-human dose estimation.

Authors:  Peng Zou; Yanke Yu; Nan Zheng; Yongsheng Yang; Hayley J Paholak; Lawrence X Yu; Duxin Sun
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

Review 2.  Coexistence of passive and carrier-mediated processes in drug transport.

Authors:  Kiyohiko Sugano; Manfred Kansy; Per Artursson; Alex Avdeef; Stefanie Bendels; Li Di; Gerhard F Ecker; Bernard Faller; Holger Fischer; Grégori Gerebtzoff; Hans Lennernaes; Frank Senner
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

Review 3.  Biomagnetic methods: technologies applied to pharmaceutical research.

Authors:  Luciana A Corá; Madileine F Américo; Ricardo B Oliveira; Cristina H R Serra; Oswaldo Baffa; Raul C Evangelista; Giselle F Oliveira; José Ricardo Aruda Miranda
Journal:  Pharm Res       Date:  2010-10-15       Impact factor: 4.200

4.  The use of BDDCS in classifying the permeability of marketed drugs.

Authors:  Leslie Z Benet; Gordon L Amidon; Dirk M Barends; Hans Lennernäs; James E Polli; Vinod P Shah; Salomon A Stavchansky; Lawrence X Yu
Journal:  Pharm Res       Date:  2008-01-31       Impact factor: 4.200

Review 5.  Mechanistic approaches to predicting oral drug absorption.

Authors:  Weili Huang; Sau Lawrence Lee; Lawrence X Yu
Journal:  AAPS J       Date:  2009-04-21       Impact factor: 4.009

Review 6.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

7.  Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.

Authors:  Wendy W J van de Sande; Ron A A Mathot; Marian T ten Kate; Wim van Vianen; Mehri Tavakol; Bart J A Rijnders; Irma A J M Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

8.  The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans.

Authors:  Urban Fagerholm
Journal:  Pharm Res       Date:  2007-08-21       Impact factor: 4.200

9.  Alginate/chitosan nanoparticles are effective for oral insulin delivery.

Authors:  B Sarmento; A Ribeiro; F Veiga; P Sampaio; R Neufeld; D Ferreira
Journal:  Pharm Res       Date:  2007-06-19       Impact factor: 4.200

10.  Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification.

Authors:  Tuba Incecayir; Yasuhiro Tsume; Gordon L Amidon
Journal:  Mol Pharm       Date:  2013-02-04       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.